Presence of CD133‐positive circulating tumor cells predicts worse progression‐free survival in patients with metastatic castration‐sensitive prostate cancer

OBJECTIVE: To investigate the clinical significance of the expression of the stemness marker CD133 in circulating tumor cells of newly diagnosed metastatic castration‐sensitive prostate cancer patients. METHODS: For this study, 104 metastatic castration‐sensitive prostate cancer patients treated at...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yunjie, Liu, Zheng, Wang, Qifeng, Chang, Kun, Zhang, Junyu, Ye, Dingwei, Kong, Yunyi, Dai, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles: Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305754/
https://www.ncbi.nlm.nih.gov/pubmed/35102615
http://dx.doi.org/10.1111/iju.14801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305754/
https://www.ncbi.nlm.nih.gov/pubmed/35102615
http://dx.doi.org/10.1111/iju.14801

Ejemplares similares